Seth, Abhishek
Mayo Clinic
Department of Hematology, Mayo Clinic, Rochester, Minnesota, USA.
Citations 2
Impact of cytogenetic abnormalities on the risk of disease progression in solitary bone plasmacytomas
Yadav, Udit , Kumar, Shaji , Greipp, Patricia T. , Buadi, Francis K. , Dingli, David , Lacy, Martha Q. , Bergsagel, P. Leif , Sher, Taimur , Hayman, Suzanne R. , Kapoor, Prashant , Binder, Moritz , Warsame, Rahma , Kourelis, Taxiarchis , Breen, William G. , Kyle, Robert A. , Bergsagel, P. Leif , Kumar, Shaji K , Dispenzieri, Angela , Greipp, Patricia T , Buadi, Francis K , Lacy, Martha Q , Roy, Vivek , Parrondo, Ricardo D , Leung, Nelson , Cook, Joselle M , Binder, Moritz , Muchtar, E , Warsame, Rahma , Kourelis, Taxiarchis , Seth, Abhishek, Lester, Scott C. , Dingli, David , Baughn, Linda B. , Dispenzieri, Angela , Ketterling, Rhett P. , Jevremović, Dragan , Fonseca, Rafaël , Ailawadhi, Sikander , Roy, Vivek , Leung, Nelson , Cook, Joselle , Muchtar, Eli , Go, Ronald S. , Lin, Yi , Seth, Abhishek, Gertz, Morie A. , Rajkumar, S. Vincent , Gonsalves, Wilson I.
Blood | July 26, 2023 | Volume: 142 | Issue: 22 | Pages: 1871-1878
Abstract Most patients with solitary bone plasmacytomas (SBP) progress to multiple myeloma (MM) after definitive radiation therapy as their primary treatment. Whether the presence of high-risk (HR) cytogenetic abnormalities by fluorescence in situ hybridization (FISH) in the clonal plasma cells, obtained either directly from the diagnostic SBP tissue or the corresponding bone marrow examination at the time of diagnosis, is associated with a shorter time to progression (TTP) to MM is unknown. This study evaluated all patients diagnosed with SBP at the Mayo Clinic from January 2012 to July 2022. The presence of del(17p), t(14;16), t(4;14), or +1q (gain or amplification) by FISH in clonal plasma cells was defined as HR. A total of 114 patients were included in this cohort, and baseline FISH was available for 55 patients (48%), of which 22 were classified as HR (40%). The median TTP to MM for patients with SBP and HR FISH was 8 months (95% confidence interval [CI], 6.3-26) compared with 42 months (95% CI, 25-not reached [NR]) in patients with SBP without HR FISH (P < .001). In a multivariate analysis, only HR FISH was a significant predictor for shorter TTP to MM, independent of minimal marrow involvement and an abnormal serum free light chain ratio at diagnosis. Deletion (17p) and gain 1q abnormalities were the most common FISH abnormalities responsible for the short TTP to MM. Thus, assessing for HR FISH abnormalities in clonal plasma cells derived from either the diagnostic SBP tissue or the staging bone marrow examination of patients with newly diagnosed SBP is feasible and prognostic for a shorter TTP to MM.
Failure of mobilization of hematopoietic stem cells associated with elevated serum levels of anti‐CD38 monoclonal antibody
Murray, David , Buadi, Francis K. , Gertz, Morie A. , Yadav, Udit , Kumar, Shaji , Gonsalves, Wilson I. , Seth, Abhishek, Buadi, Francis K , Gertz, Morie A , Kumar, Shaji K , Gonsalves, Wilson , Seth, Abhishek
European Journal of Haematology | May 20, 2023 | Volume: 111 | Issue: 2 | Pages: 318-321
AbstractDaratumumab is an anti‐CD38 antibody that is increasingly incorporated in induction regimens for treating patients with newly diagnosed multiple myeloma (NDMM). Previous reports have demonstrated a lower yield of hematopoietic stem cells (HSCs) after induction with daratumumab; however, none of them reported a failure to collect an adequate number of HSCs. We describe a case of adequate HSC mobilization failure in a patient who inadvertently received excessive doses of daratumumab and was confirmed by higher‐than‐expected circulating levels of daratumumab by mass spectrometry. Eventual clearance of circulating daratumumab was associated with the successful mobilization and harvesting of HSCs.